Want to see AU:CBL full AI Analyst Report?

Control Bionics Ltd. (CBL) Price & Analysis

3 Followers

CBL Stock Chart & Stats

AU$0.06

AU$0.00(0.00%)

At close: Jan 09 4:00 PM EST

AU$0.06

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.03 - AU$0.10

Previous CloseN/A

Volume65.91K

Average Volume (3M)173.99K

Market Cap

AU$30.93M

Enterprise ValueAU$25.95M

Total Cash (Recent Filing)AU$3.06M

Total Debt (Recent Filing)AU$258.10K

Price to Earnings (P/E)―

Beta-0.13

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.02

Shares Outstanding441,897,670

10 Day Avg. Volume327,267

30 Day Avg. Volume173,987

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)1.44

Price to Sales (P/S)1.29

P/FCF Ratio-1.73

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Top-line GrowthSustained ~16% revenue growth indicates persistent demand for the company’s assistive-technology products. Over 2–6 months this supports scale benefits, deeper market penetration and the potential to leverage fixed costs to improve operating margins if growth continues.

Conservative LeverageA conservative capital structure with low leverage provides financial flexibility during negative earnings periods. That reduces near-term refinancing and interest burdens, enabling management to prioritize R&D, product development and strategic partnerships without immediate solvency pressure.

Niche Assistive-Technology FocusA clear niche in assistive human–machine interfaces creates domain expertise and higher switching costs with clinical and end-user customers. Structural demand for accessibility tech and specialized products supports durable revenue opportunities and partnerships over the medium term.

Bears Say

Negative ProfitabilityPersistent net losses and negative EBIT margins signal the company struggles to convert gross profit into operating profit. Over months this undermines capacity to self-fund growth, pressures margins, and increases reliance on external capital to sustain operations and commercialization.

Weak Cash GenerationNegative operating cash flow and falling free cash flow create liquidity risk and heighten the probability of needing external financing. This can constrain investment in product development, sales expansion and customer support, limiting durable growth unless cash conversion improves.

Negative Return On EquityA negative ROE indicates shareholder capital is not delivering positive returns, weakening investor confidence and making equity raises dilutive or difficult. Structurally, this points to deeper profitability or efficiency issues that must be resolved to sustain long-term growth.

Control Bionics Ltd. News

Control Bionics Options Lapse Adjusts ASX-Listed Capital Structure

The latest update is out from Control Bionics Ltd. ( ($AU:CBL) ). Control Bionics Limited has notified the...

5d ago

CBL

Control Bionics Issues New Unquoted Employee Options

Control Bionics Ltd. ( ($AU:CBL) ) has shared an announcement. Control Bionics Limited, an ASX-listed developer of assistive...

5d ago

CBL

Control Bionics Calls Shareholder Meeting to Approve Major Equity Issuances

Control Bionics Ltd. ( ($AU:CBL) ) has provided an announcement. Control Bionics Limited has called a general meeting...

6d ago

CBL

Control Bionics Issues Nearly 30 Million New Shares Under Regulatory Exemption

An announcement from Control Bionics Ltd. ( ($AU:CBL) ) is now available. Control Bionics Limited has issued 29,935,788...

11d ago

CBL

Control Bionics Lists Nearly 30 Million New Shares on ASX

Control Bionics Ltd. ( ($AU:CBL) ) just unveiled an update. Control Bionics Limited has applied for quotation on...

11d ago

CBL

Control Bionics Showcases Neural-Signal Platform at LSI Asia Medtech Summit

Control Bionics Ltd. ( ($AU:CBL) ) has provided an announcement. Control Bionics Limited, a neurotechnology firm listed on...

11d ago

CBL

Control Bionics Plans Major Share Placement to Fund Growth

Control Bionics Ltd. ( ($AU:CBL) ) just unveiled an update. Control Bionics Ltd. has lodged a notice with...

17d ago

CBL

Control Bionics Launches Securities Purchase Plan to Raise Capital

Control Bionics Ltd. ( ($AU:CBL) ) has shared an announcement. Control Bionics Limited has announced a new share...

17d ago

CBL

Control Bionics Plans 29.6 Million-Share Placement to Fund Growth

Control Bionics Ltd. ( ($AU:CBL) ) has issued an update. Control Bionics Ltd. has notified the ASX of...

17d ago

CBL

Control Bionics Raises Up to A$10m to Accelerate Neurotechnology Expansion

Control Bionics Ltd. ( ($AU:CBL) ) has provided an announcement. Control Bionics has secured firm commitments to raise...

17d ago

CBL

CBL FAQ

What was Control Bionics Ltd.’s price range in the past 12 months?

Control Bionics Ltd. lowest share price was AU$0.03 and its highest was AU$0.10 in the past 12 months.

What is Control Bionics Ltd.’s market cap?

Control Bionics Ltd.’s market cap is AU$30.93M.

When is Control Bionics Ltd.’s upcoming earnings report date?

Control Bionics Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 47 days.

How were Control Bionics Ltd.’s earnings last quarter?

Control Bionics Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.011.

Is Control Bionics Ltd. overvalued?

According to Wall Street analysts Control Bionics Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Control Bionics Ltd. pay dividends?

Control Bionics Ltd. does not currently pay dividends.

What is Control Bionics Ltd.’s EPS estimate?

Control Bionics Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Control Bionics Ltd. have?

Control Bionics Ltd. has 441,897,670 shares outstanding.

What happened to Control Bionics Ltd.’s price movement after its last earnings report?

Control Bionics Ltd. reported an EPS of -AU$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.667%.

Which hedge fund is a major shareholder of Control Bionics Ltd.?

Currently, no hedge funds are holding shares in AU:CBL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Control Bionics Ltd. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-98.14%

Trailing 12-Months

Asset Growth

12.36%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Control Bionics Ltd.

Operating in Australia and North America, Control Bionics Limited and its subsidiaries specialize in the innovation, development, and market introduction of sophisticated assistive communication technologies. The company's offerings include the NeuroNode Trilogy and NeuroNode3 systems, which empower individuals facing speech and mobility challenges to control computers for speech generation, electronic correspondence, leisure activities, and remote operation of other devices. Control Bionics also provides Cosmos Connect, a versatile interface capable of managing diverse equipment like wheelchairs, robotic dining aids, and gaming consoles. Additionally, they offer Uno Touch, a dedicated speech-generating device, alongside various other sensors for a broad spectrum of uses. Founded in 2005, the entity was initially named Control Bionics Holdings Pty Limited before rebranding as Control Bionics Limited in September 2020. The company's base of operations is situated in Camberwell, Australia.